KalVista Pharmaceuticals (KALV) Leases (2019 - 2025)
KalVista Pharmaceuticals recorded quarterly Leases of $5.2 million in Q3 2025, down 6.84% quarter-over-quarter from $5.5 million in Q2 2025, and down 11.85% year-over-year from $5.9 million in Q3 2024.
KalVista Pharmaceuticals' Leases history runs 7 years deep, the most recent figure standing at $5.2 million for Q3 2025.
- In Q3 2025, Leases fell 11.85% year-over-year to $5.2 million; the TTM figure through Jul 2025 stood at $5.2 million (down 11.85% YoY), while the FY2025 annual figure was $5.5 million, down 19.88% from the prior year.
- Leases came in at $5.2 million for Q3 2025 at KalVista Pharmaceuticals, down from $5.5 million in the prior quarter.
- In the past five years, Leases ranged from a high of $8.7 million in Q3 2022 to a low of $1.7 million in Q1 2021.
- A 5-year average of $6.7 million and a median of $7.0 million in 2024 frame the typical range for Leases.
- Across the five-year window, Leases soared 433.26% in 2021 and slipped 22.61% in 2024, its largest moves.
- KalVista Pharmaceuticals' Leases stood at $7.0 million in 2021, then rose by 20.2% to $8.4 million in 2022, then dropped by 12.76% to $7.3 million in 2023, then fell by 23.62% to $5.6 million in 2024, then fell by 7.34% to $5.2 million in 2025.
- According to Business Quant data, Leases over the past three periods registered $5.2 million, $5.5 million, and $5.6 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 61,822.50 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 189.30 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 5.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 5.17 Mn |
| Apr 30, 2025 | 5.54 Mn |
| Dec 31, 2024 | 5.57 Mn |
| Oct 31, 2024 | 5.86 Mn |
| Jul 31, 2024 | 5.86 Mn |
| Apr 30, 2024 | 6.92 Mn |
| Jan 31, 2024 | 7.05 Mn |
| Oct 31, 2023 | 7.30 Mn |
| Jul 31, 2023 | 7.57 Mn |
| Apr 30, 2023 | 7.82 Mn |
| Jan 31, 2023 | 8.10 Mn |
| Oct 31, 2022 | 8.37 Mn |
| Jul 31, 2022 | 8.66 Mn |
| Apr 30, 2022 | 7.86 Mn |
| Jan 31, 2022 | 8.18 Mn |
| Oct 31, 2021 | 6.96 Mn |
| Jul 31, 2021 | 7.21 Mn |
| Apr 30, 2021 | 5.76 Mn |
| Jan 31, 2021 | 1.65 Mn |
| Oct 31, 2020 | 1.31 Mn |
| Jul 31, 2020 | 1.48 Mn |
| Apr 30, 2020 | 1.61 Mn |
| Jan 31, 2020 | 1.50 Mn |
| Oct 31, 2019 | 1.63 Mn |
| Jul 31, 2019 | 1.74 Mn |
| Apr 30, 2019 | 505,000.00 |